Drug intelligence / Profile preview

DHP2302R1

Development stage: Unknown
Lead developer: Daehwa Pharmaceutical
Modality: Small Molecules

Overview

DHP2302R1 is a small molecule investigational drug developed by DAE HWA PHARM. It is currently being evaluated in phase 1 clinical trials to assess its safety and pharmacokinetic drug-drug interactions, both alone and in combination with another investigational agent, DHP2302R2. The primary study population has been healthy adult volunteers in South Korea. The specific mechanism of action, molecular target(s), therapeutic area(s), and intended indications for DHP2302R1 have not been publicly disclosed as of the latest available data.

Beyond the preview

Go deeper on DHP2302R1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHP2302R1.

Explore the full profile